<?xml version='1.0' encoding='utf-8'?>
<document id="27365092"><sentence text="Study of warfarin utilization in hospitalized patients: analysis of possible drug interactions." /><sentence text="Background Drug-drug interactions in patients taking warfarin may contribute to a higher risk of adverse events" /><sentence text=" Objective To identify and evaluate the prevalence and characteristics of potential DDIs with warfarin" /><sentence text=" Methods A cross-sectional study was performed in a Brazilian tertiary hospital" /><sentence text=" The electronic prescriptions of the patients receiving warfarin between January 2004 and December 2010 were analyzed" /><sentence text=" Socio-demographic, clinical, and therapeutic variables were collected" /><sentence text=" Warfarin drug-drug interactions were classified as either risk A, B, C, D, or X according to the Lexi-Interact™ Online database" /><sentence text=" Results A total of 3048 patients were identified who were prescribed warfarin"><entity charOffset="70-78" id="DDI-PubMed.27365092.s8.e0" text="warfarin" /></sentence><sentence text=" Of the 154,161 total drug prescriptions issued, 42,120 (27" /><sentence text="3 %) were for warfarin" /><sentence text=" Evaluation of the prescriptions showed that 63" /><sentence text="1 and 0" /><sentence text="1 % of patients received concomitant drugs classified as having class D or X risk" /><sentence text=" It was found that 20,539 (48" /><sentence text="7 %) prescriptions had at least one drug with a D or X risk" /><sentence text=" Patients were prescribed an average of 1" /><sentence text="4 (±0" /><sentence text="4) concomitant medications with a class D or X warfarin-DDI risk, the most frequent being acetylsalicylic acid and amiodarone"><entity charOffset="90-110" id="DDI-PubMed.27365092.s18.e0" text="acetylsalicylic acid" /><entity charOffset="115-125" id="DDI-PubMed.27365092.s18.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.27365092.s18.e0" e2="DDI-PubMed.27365092.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27365092.s18.e0" e2="DDI-PubMed.27365092.s18.e1" /></sentence><sentence text=" Conclusion The results demonstrate a high prevalence of concomitant drug prescriptions with the potential for clinically relevant DDIs with warfarin, the most frequent being acetylsalicylic acid and amiodarone"><entity charOffset="175-195" id="DDI-PubMed.27365092.s19.e0" text="acetylsalicylic acid" /><entity charOffset="200-210" id="DDI-PubMed.27365092.s19.e1" text="amiodarone" /><pair ddi="false" e1="DDI-PubMed.27365092.s19.e0" e2="DDI-PubMed.27365092.s19.e0" /><pair ddi="false" e1="DDI-PubMed.27365092.s19.e0" e2="DDI-PubMed.27365092.s19.e1" /></sentence><sentence text=" " /></document>